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cancer patients. The aim of this study was evaluate the plasma con-
centrations of oxycodone and its demethylates and opioid-induced 
adverse effects based on cachexia stage in cancer patients receiving 
oxycodone.
Patients (or Materials) and Methods: Seventy patients receiving 
oxycodone for cancer pain at Hamamatsu University Hospital were 
enrolled. Cachexia was evaluated using the Glasgow Prognostic Score 
(GPS). Predose plasma concentrations of oxycodone, oxymorphone, 
and noroxycodone were determined at the titration dose. Opioid-
induced adverse effects were monitored for 2 weeks after the titra-
tion.
Results: Fourteen patients had a GPS of 0, 27 a GPS of 1, and 29 a 
GPS of 2. Plasma concentrations of oxycodone and oxymorphone 
but not noroxycodone in patients with a GPS of 2 were significantly 
higher than that with a GPS of 0. The metabolic ratios of noroxyco-
done but not oxymorphone to oxycodone in patients with a GPS of 1 
and 2 were significantly lower than in those with a GPS of 0. A higher 
GPS was associated with a higher incidence of somnolence, while 
the GPS did not affect the incidence of vomiting. Plasma concentra-
tions of oxycodone and oxymorphone were not associated with the 
incidence of adverse effects.
Conclusion: Cancer cachexia raised the plasma exposures of oxy-
codone and oxymorphone through the reduction of CYP3A but not 
CYP2D6. Although the cachexia elevated the incidence of somno-
lence, alterations in their pharmacokinetics were not associated with 
the incidence.
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Introduction: Many issues remain to be solved in regard to cannabi-
noid disposition, elimination time profiles and correlation between 
oral fluid (OF) and whole blood (WB) concentrations. Delta-9-
tetrahydrocannabinol (THC) in OF is usually indicative of a relatively 
recent cannabis exposure, but the study of other cannabinoids in OF 
and WB could also be helpful as a confirmatory test when applied 
for legal purposes.
Patients (or Materials) and Methods: A randomized, blinded, 2-way 
crossover study was conducted in 48 healthy volunteers (23 heavy 
and 25 occasional cannabis smokers) who received by smoking on 
each period, in random sequence, a cannabis joint (containing bed-
robinol, 11% THC, and traces of cannabidiol- CBD) or a placebo. 
WB was collected up to 2.5 hours after smoking. An additional WB 
sample at 3.5 hours, and OF samples were collected in heavy smok-
ers. Storage at –20°C and liquid-liquid extraction preceded analy-
sis by liquid chromatography-tandem mass spectrometry. THC, 
11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC 
(THCCOOH) were measured in WB. THC, THCCOOH, cannabi-
nol (CBN), CBD and delta-9-tetrahydrocannabinolic acid A (THC-A) 
were investigated in OF. WB pharmacokinetic parameters of THC 
and its metabolites were compared in heavy and occasional smokers. 
Correlations for these parameters between OF and WB were studied 
in heavy smokers.
Results: Before smoking, a significant difference (P < 0.001) was 
found in WB THCCOOH between heavy and occasional smokers: 
median THCCOOH was 20.1 µg/L (range, 2.50–93.9) and 0.14 µg/L 
(range, 0–16.6) respectively. No significant difference was found in 
WB for THC maximal concentrations (Cmax): median Cmax were 86.5 
µg/L (range, 37.1–192) and 75.1 µg/L (range, 8.20–168) respectively. 
Elimination half-lives (t1/2) in WB were also not significantly differ-
ent: median THC T1/2 were 0.97 hours (range, 0.55–1.87) and 0.84 
hour (range, 0.69–1.45) respectively; and median THCCOOH t1/2 
were 3.89 hours (range, 1.68–9.16) and 3.33 hours (range, 1.59–
17.3) respectively. Differences in the area under the curve (AUC) 
between both groups, were marginally significant for THC (P = 0.01) 
but highly significant (P < 0.001) for 11-OH-THC and THCCOOH. 
No correlation between WB and OF was found in heavy smokers for 
Cmax or AUC.
Conclusion: Our results suggest that the smoking regimen (heavy/
occasional) do not influence the elimination kinetic of cannabinoids 
in WB but do influence the initial THCCOOH level. No correlation 
was found between WB and OF for THC or THCCOOH parameters.
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Introduction: Methadone is known to be associated with pro-
longation of corrected QT time (QTc). Excretion of methadone 
is primarily renal in patients with normal renal function. It is 
unknown to what extent hemodialysis removes methadone. We 
investigated methadone kinetics and QTc during hemodialysis 
in methadone maintenance treatment (MMT) patients with end-
stage renal disease.
Patients (or Materials) and Methods: The Regional Ethics 
Committee approved the study. Data are given as median (range). 
Four patients with end-stage renal failure, 1 female and 3 males, 46 
(43–53) years, stabilized on methadone were included. Methadone 
was measured by UPLC-MMS in serum and hemodialysates col-
lected before morning methadone intake, every 30 minutes during 4 
hours hemodialysis and before afternoon dose, and in urine sampled 
at the end of hemodialysis. ECGs were recorded every 30 minutes 
during hemodialysis, and QT time was measured in lead v2 using 
tangential method and QTc was calculated with Bazzet’s formula. 
ECGs were read serially for each patient with blinding of number-
ing. Several routine biochemical tests were performed before and 
after hemodialysis.
Results: The daily methadone dose was 100 (60–120) mg. Serum-
methadone increased from Cmin of 1124 (547–1581) nmol/L to 
Cmax of 1806 (1237–2098) nmol/l after 85 (40–120) minutes. The 
apparent half-life of methadone was 12 (6.3–25) hours. A total of 
2.30 (1.25–3.70) % and 0.14 (0.03–0.26) % of daily methadone 
intake was collected, respectively, in hemodialysate and urine dur-
ing 4 hours. Renal clearance of methadone was 0.67 (0.31–1.20) 
mL/min, methadone clearance of hemodialysis was 17.10 (13.67–
20.61) mL/min and AUC of dose interval was 253.5 mg min/L. QTc 
increased from 395 (369–406) ms to 452 (407–479) ms with P = 
0.068,Wilcoxon paired comparison. The maximum QTc occurred 
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180 (135–219) min after methadone intake. QTc did not increase 
with increasing methadone concentrations, R2 = 0.0015.
Conclusion: Another route than renal and hemodialysis must 
eliminate methadone in these patients as only a small amount of 
methadone was lost in hemodialysate and urine. All values of serum-
methadone were comparable with those seen in patients with nor-
mal renal function after similar daily methadone doses. QTc tended 
to increase during hemodialysis. However, this increase was not 
concentration-dependent on methadone.
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Introduction: Different pharmaceutical formulations of the car-
diovascular drug, calcium antagonist, diltiazem may reflect in its 
different bioavailability, that may subsequently influence the pharma-
cological effects. The primary purpose of the study was to compare 
the cardiovascular activities of 2 different modified-release formula-
tions of diltiazem: gelatine capsules with micropellets and film-coated 
tablets. Secondary, we would like to consider if the pharmacodynamic 
data may be useful in concluding the therapeutic equivalence of dif-
ferent diltiazem formulations.
Patients (or Materials) and Methods: The study was conducted on 
a group of healthy, male subjects that participated in a randomized, 
2-way cross-over bioavailability trial of 2 diltiazem MR formulation 
after single and multiple doses of 120 mg. During the course of the 
study standard bioavailability parameters (AUCt, AUCinf, Cmax, 
Cmin) for both formulations were calculated. Bioequivalence tasting 
was based on Shuirmann’s procedure. Pharmacological effects were 
evaluated after single- and multiple-dose administration. Blood pres-
sure, ECG parameters (QTc, PQ) and heart rate variability (HRV) 
were measured continuously (ECG Holter monitoring) up to 24 
hours after administration and analyzed at the same time points as 
pharmacokinetic samples to plot the effect-time profile. Classical 
HRV analysis in time and frequency domains was conducted and 
several components of HRV estimated (RR, RMS, SDNN, PNN, 
LF, HF and LF/HF). Mean values at each time point and calculated 
effect parameters (AUEC, Emax, TEmax) were compared statistically 
between formulations (t-test, p< 0.05). Pharmacological data were 
correlated with pharmacokinetic parameters.
Results: Bioavailability analysis concluded inequivalence (CI for 
Cmax(single): 0.78–0.95). In pharmacodynamic analysis the only 
statistically significant difference was observed after multiple doses of 
diltiazem for the extend of PQ effect (AUEC0-8 [ms*h]; P = 0.0289). 
Differences for the other calculated BP, ECG and HRV parameters were 
statistically insignificant (p ≥ 0.05), although distinct diversity have 
been observed. Bioequivalence couldn’t be concluded in the basis of 
PD data. High variability of values was observed (CV% > 50%–60%).
Conclusion: Differences in the most of tested pharmacodynamic 
parameters were found between 2 diltiazem formulations. Although 
most of them were statistically insignificant they may indicate the 
diversity of 2 tested modified-release oral diltiazem formulations in 
respect of bioavailability and pharmacodynamics. Because of their 
high variability cardiovascular parameters can be used in the estima-
tion of therapeutic equivalence only in limited range.
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Introduction: The objectives of this study were to determine the 
pharmacokinetics (PK) and safety of single-dose sugammadex (16 
mg/kg) in healthy Chinese adult volunteers. The 16-mg/kg dose was 
chosen because this is the highest recommended dose for use in clini-
cal practice, for immediate reversal of NMB.
Patients (or Materials) and Methods: In this open-label study, 
healthy Chinese subjects received intravenous (IV) sugammadex 
(16 mg/kg) as a 10-second bolus infusion. Blood samples were 
collected pre-sugammadex and at regular intervals up to 24 hours 
post-sugammadex for PK assessment. Safety was also evaluated, 
via adverse events (AEs), vital signs, ECG, and laboratory param-
eters.
Results: Twelve subjects were included (6 male; 6 female). 
Geometric mean (CV%) weight was 58.3 (3.7%) kg and 53.6 
(9.8%) kg for males and females, respectively. The main pharma-
cokinetic parameters are shown in the Table. After the 16-mg/kg 
sugammadex dose, plasma sugammadex concentrations showed 
a polyexponential decline over time, indicating 2 to 3 compart-
ments, with an overall geometric mean (CV) terminal half-life 
(t½) of 145 (17.9%) minutes (139 [17.7%]) minutes for males; 
152 [18.6%] minutes for females). No influence of gender on the 
PK of sugammadex was observed. Three subjects experienced an 
AE (dysgeusia of mild intensity in all cases), which was consid-
ered possibly or probably related to sugammadex. Dysgeusia is 
a known adverse drug reaction in healthy conscious subjects. 
There were no clinically significant changes in vital signs, ECG, 
or laboratory parameters.
Conclusion: After a single IV bolus infusion dose of sugammadex 16 
mg/kg in healthy Chinese subjects, peak sugammadex concentration 
was 197 μ g/mL, clearance was 99.7 mL/min, and volume of distribu-
tion was 10.5 L. No influence of gender on the PK of sugammadex 
was observed. Overall between-subject variability on clearance and 
volume of distribution was ~10%. Sugammadex was generally well 
tolerated in Chinese volunteers.
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Table.  Geometric mean (CV %) pharmacokinetic parameters for 
sugammadex 16 mg/kg in Chinese subjects.
male (n = 6) Female (n = 6) Total (n = 12)
Tmax, min
a> 2.0 (2.0–3.0) Tmax, mina 3.0 (2.0–3.0) Tmax, mina 2.5 (2.0–3.0)
Cmax, µg/mL 214 (27.7%) Cmax, µg/mL 182 (10.6%) Cmax, µg/mL 197 (21.7%)
CL, mL/min 104 (12.5%) CL, mL/min 95.8 (12.4%) CL, mL/min 99.7 (12.6%)
Vss, L 10.7 (10.7%) Vss, L 10.3 (7.4%) Vss, L 10.5 (9.0%)
aValues given as median (range). Tmax = time to maximum observed concentration;  
Cmax = maximum observed concentration; CL = clearance, Vss = volume of distribution 
at equilibrium.
